Tessera therapeutics stocks code#
Tessera therapeutics stocks series#

Sigal is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as the company’s Chief Scientific Officer and President of R&D from 2004 until 2013.

He previously served on the Board of Directors for the gene therapy company, Spark Therapeutics. He co-chairs the Scientific Advisory Board for Amgen and is a member of the Scientific Steering Committee for the Sean Parker Institute for Cancer Immunology. He currently serves as a senior advisor to the healthcare team of New Enterprise Associates and is a member of the Board of Directors for Adaptimmune Therapeutics, Surface Oncology, Vir Therapeutics, and Affinia. Sigal brings decades of clinical experience in drug discovery, drug development, and corporate strategy to Tessera’s Board of Directors. I am excited to welcome Elliott and Mary to the team at Tessera and look forward to working closely with them as we advance Tessera’s Gene Writing platform and pioneer the future of genetic medicine,” said Noubar Afeyan, Ph.D., Co-founder and Chairman of the Board, Tessera and CEO of Flagship Pioneering.ĭr. “The next frontier in medicine will be therapeutics that cure and provide enduring protection against disease.

Tessera therapeutics stocks code#

Together, they offer decades of experience that will help us rapidly grow Tessera and to fulfill our mission of curing diseases by writing in the code of life.” “Elliott has overseen more than a dozen new medications on their way to market, and Mary has guided major strategic, fundraising, and partnership efforts. “Elliott and Mary bring phenomenal leadership, experience, and creativity to Tessera’s Board of Directors,” said Geoffrey von Maltzahn, Ph.D., CEO and Co-Founder of Tessera.

Tessera therapeutics stocks series#

as Senior Vice President of Rare Diseases Program Strategy and Operations, and a $230 million Series B fundraising round in January. as Chief Operating Officer, and Lin Guey, Ph.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. This announcement represents the latest key development for Tessera, following the March appointments of David Davidson, M.D. Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. Tessera Therapeutics taps former BeiGene CFO Howard Liang to join race to CRISPR 3.New Board Members Will Help Advance ‘Gene Writing’ Platform and Mission to Cure Disease by Writing in the Code of Life Tessera Therapeutics Announces R&D Collaboration with Cystic Fibrosis Foundation as Part of a Portfolio of Complementary Technologies Advanced by Flagship’s Pioneering Medicines to Treat Cystic Fibrosis Tessera Therapeutics Adds New Executives to its Leadership Team as the Company Continues to Pioneer Gene Writing™ Technology as New Category in Genetic MedicineĬystic fibrosis group partners with Moderna founder to find better, potentially curative treatmentsĬystic Fibrosis Foundation, Flagship Pioneering team up to develop new treatments for deadly diseaseįleet of Flagship biotechs will get up to $110M for new cystic fibrosis treatmentsįlagship and the Cystic Fibrosis Foundation team up on a novel research pact to chase down potential cures How technology could transform drug research in 2022 Scientists Race to Make Really Big Changes to Your Genes Novel Gene Editing Systems Come Into Their Own Here's how they could upend biotech in 2022 These gene-editing startups are aiming to solve one of CRISPR's biggest problems. Navigating Recruitment and Hiring Amid ‘The Great Resignation’: Bec Lillie, Chief Human Resources Officer, Tessera Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platformįinance Watch: Tessera Secures $300m-Plus To Write New Genesįlagship-founded Tessera fuels up with $300M 'to go on a really big adventure' in gene editingįlagship-Backed Tessera Raises $300 Million for Gene-Fixing TechĪpril 19 Quick Takes: Flagship-founded Tessera raises $300M from broad syndicate Tessera snags $300M+ for gene writing techįlagship-backed 'gene-writing' startup Tessera raises $300M Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer Former AbbVie executive Severino joins Flagship-backed startup as CEO